ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 331 filers reported holding ROYALTY PHARMA PLC in Q4 2022. The put-call ratio across all filers is 0.58 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,560,550 | -92.2% | 57,500 | -91.2% | 1.05% | -90.9% |
| Q2 2023 | $20,002,211 | -45.7% | 650,690 | -36.3% | 11.50% | -45.0% |
| Q1 2023 | $36,829,650 | +3.9% | 1,022,194 | 0.0% | 20.91% | -0.1% |
| Q4 2022 | $35,462,047 | -13.7% | 1,022,194 | 0.0% | 20.94% | -12.7% |
| Q3 2022 | $41,072,000 | -7.1% | 1,022,194 | -2.8% | 24.00% | -3.2% |
| Q2 2022 | $44,222,000 | -58.4% | 1,051,895 | -61.4% | 24.80% | -40.2% |
| Q1 2022 | $106,277,000 | -42.0% | 2,727,854 | -40.7% | 41.47% | -15.9% |
| Q4 2021 | $183,355,000 | -35.5% | 4,601,152 | -41.5% | 49.30% | -19.0% |
| Q3 2021 | $284,152,000 | -25.5% | 7,862,542 | -15.5% | 60.85% | -8.3% |
| Q2 2021 | $381,307,000 | +0.4% | 9,302,445 | +6.9% | 66.33% | -13.0% |
| Q1 2021 | $379,735,000 | -64.7% | 8,705,551 | -59.5% | 76.23% | -12.9% |
| Q4 2020 | $1,074,938,000 | – | 21,477,282 | – | 87.53% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $244,378,000 | 79.54% |
| Vantage Consulting Group Inc | 7,862,542 | $284,152,000 | 60.85% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $96,878,000 | 60.36% |
| Indie Asset Partners, LLC | 701,323 | $25,346,000 | 20.53% |
| HARVARD MANAGEMENT CO INC | 7,142,856 | $258,143,000 | 15.13% |
| Bleichroeder LP | 1,115,980 | $40,332,000 | 6.55% |
| Overbrook Management Corp | 785,132 | $28,375,000 | 6.16% |
| Geo Capital Gestora de Recursos Ltd | 194,305 | $7,022,000 | 3.21% |
| Brown University | 621,759 | $22,470,000 | 3.05% |
| Graypoint LLC | 610,584 | $22,067,000 | 2.71% |